The German G-BA just published the added-benefit assessment for Takeda/Tigenix’ Darvadstrocel, link to the G-BA webpage here: G-BA Darvadstrocel

Darvadstrocel has orphan drag status in Europe and therefore it is assumed by G-BA to bring some kind of benefit to patients. A consultation process will be held until the end of September and the final G-BA resolution with be published end of November 2018.

G-BA have assessed Darvadstrocel added benefit based on the pivotal trial ADMIRE-CD with the strongest evidence of effect coming from time-to-remission data both at 24 and 52 weeks.

Previous PostNext Post